컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

European Association for the Study of the Liver Congress 2025 (EASL 2025)

07 May- 10 May, 2025, Netherlands

Are statins protective against HCC?

2025-08-07

In a study presented at EASL 2025, the use of statins appears to be associated with a reduced risk of hepatocellular carcinoma (HCC) and slower progression of liver fibrosis in individuals with chronic liver disease (CLD).
Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC

2025-08-07

A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.
CDK4/6 inhibitor-induced liver injury common in breast cancer

2025-08-07

Liver injury occurs in around one in 20 patients treated with cyclin-dependent kinase 4/6 inhibitors for metastatic breast cancer, according to a multicentre retrospective study in Spain.
Diabetes in CHD patients ups risk of hepatocellular carcinoma

2025-08-07

The presence of diabetes mellitus predisposes patients with chronic hepatitis B (CHB) to a higher risk of developing hepatocellular carcinoma (HCC), reveals a study presented at EASL 2025.
Does long-term albumin therapy prolong survival in cirrhotic patients?

2025-08-07

Long-term human albumin (LTA) therapy among cirrhotic patients with existing or prior ascites and acute decompensation results in improved transplant-free survival (TFS), mortality, and disease-related complications, according to the results of the PRECIOSA trial.
Efruxifermin reduces fibrosis in MASH cirrhosis

2025-08-07

The long-acting, bivalent fibroblast growth factor 21 analogue efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) in the phase 2b SYMMETRY trial.
Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

2025-08-07

The addition of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to pegylated interferon (PEG-IFN) alfa led to a higher rate of hepatitis B surface antigen (HBsAg) loss in patients with chronic HB virus (HBV) infection compared with PEG-IFN alfa alone, according to the ENSURE study presented at EASL 2025.
Investigational Gal3 inhibitor NAVIGATEs MASH treatment field

2025-08-07

The galectin-3 (Gal3) inhibitor belapectin, given at the established 2-mg dose, demonstrates its treatment potential for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension (PH) in the phase IIb/III NAVIGATE trial.
Linerixibat quells cholestatic itch in PBC, enabling better sleep

2025-08-07

The ileal bile acid transporter inhibitor linerixibat provides rapid and substantial relief from cholestatic pruritus, in turn reducing associated sleep disturbances, in patients with primary biliary cholangitis (PBC), as shown in the global, phase III GLISTEN trial.
Norucholic acid puts brakes on PSC progression

2025-08-07

In patients with primary sclerosing cholangitis (PSC), treatment with the semi-synthetic bile acid derivative norucholic acid is safe and demonstrates potential in slowing disease progression, according to the week-96 data from the pivotal phase III NUC-5 study.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브